NCT03201562已完成2 期
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
LENZ Therapeutics, Inc1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2017年4月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye
研究概览
简要总结
To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in the treatment of early to moderate presbyopia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 48 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be able and willing to provide written informed consent and sign Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed;
- •Be able and willing to follow all instructions and attend study visits;
- •Be 48-64 years of age of either sex and any race or ethnicity at visit 1;
- •Be an early to moderate presbyope determined by screening monocular best-corrected distance visual acuity (VA) at 45 cm
- •Be able and willing to avoid all disallowed medications for the appropriate washout period and during the study without significant risk to the subject.
排除标准
- •Be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy;
- •Have known contraindications or sensitivity to the use of any of the study medications(s) or their components;
- •Have an active ocular infection at visit 1 (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (eg, moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye;
- •Have moderate or severe dry eye;
- •Have clinically significant abnormal lens findings (eg cataract) including early lens changes and/or any evidence of a media opacity in either eye;
- •Have dark-adapted pupillometry measurements of < 4.0 mm in either eye;
- •Have intraocular pressure (IOP) that is less than 5 millimeters of mercury (mmHg) or greater than 22 mmHg in either eye documented at visit 1, or have a prior diagnosis of ocular hypertension or glaucoma or currently being treated with any type of topical IOP lowering (glaucoma) medication at visit 1;
- •Have abnormal findings on dilated fundus exam in either eye documented within 3 months of visit 1 or a known history of retinal detachment or clinically significant retinal disease in either eye;
- •Have a known history or diagnosis in the past of: iritis, scleritis or uveitis, whether active or inactive;
- •Have had surgical intervention (ocular or systemic) within 6 months prior to visit 1, or planned surgical intervention within 30 days after visit 4;
- •Have undergone refractive eye surgery (incisional keratotomy, photorefractive keratectomy [PRK], laser in situ keratomileusis [LASIK], laser-assisted sub-epithelial keratectomy [LASEK]), corneal inlay procedures, cataract extraction, or intraocular lens placement;
- •Use artificial tears or lubricant eye ointment on a daily basis;
- •Have an inability or refuse to discontinue soft contact lens wear 7 days prior to study visit 1 and rigid gas permeable (RGP) contact lens wear 14 days prior to visit 1 and during the study;
- •Use any of the following disallowed medications during the 2 weeks (14 days) prior to visit 1 and during the study:
- •narcotic (opiate class) pain medication (eg, codeine, OxyContin®, Vicodin®, Tramadol®)
- •bladder medication (eg Urecholine®, bethanechol)
- •antipsychotics
- •antidepressants
- •attention -deficit/hyperactivity disorder (ADHD) medications
- •alpha-blockers (eg, tamsulosin, Flomax®, Jayln®, Uroxatral®, Rapaflo®)
- •anticholinergics (eg, atropine, belladonna, benztropine, dicyclomine, donepezil, hyoscyamine, propantheline, scopolamine, trihexphenidyl)
- •muscarinic receptor agonists or cholinergic agonists (eg, Salagen®, Evoxac®)
- •over-the-counter (OTC) or prescription antihistamines or decongestants
- •any prescribed topical ophthalmic medications
- •recreational drug use (eg, marijuana, methadone, heroin, cocaine);
- •Have a diagnosis of diabetes mellitus or a history of elevated blood sugar;
- •Have a condition or a situation, which in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation, including but not limited to unstable: cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
研究组 & 干预措施
Aceclidine+tropicamide combination
Experimental
Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
干预措施: Aceclidine+tropicamide combination (Drug)
Aceclidine
Active Comparator
Aceclidine single dose
干预措施: Aceclidine (Drug)
Vehicle
Sham Comparator
Vehicle single dose
干预措施: Vehicle (Drug)
结局指标
主要结局
Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye
时间窗: 1 hour post-treatment
Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPHBenign Prostatic HyperplasiaNCT01966614Sophiris Bio Corp479
已完成
2 期
Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry EyeDry Eye SyndromeNCT00799552Resolvyx Pharmaceuticals, Inc232
已完成
1 期
Extension Study of PRX-102 for up to 60 MonthsFabry DiseaseNCT01981720Protalix15
已完成
2 期
Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract SurgeryInflammationPainCataractNCT02329743A.T. Resolve SARL256
已完成
2 期
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) ModelAllergic ConjunctivitisNCT01332188Aciex Therapeutics, Inc.101